HistoryofMedicine,2022,8(2):826-832
DOI:10.48047/HM.V8.I2.2022.826-832

Targeting Obesity: Pharmacological Therapies, Biochemical and physiological Mechanisms and Renal Stone Risk – Current Drugs and Future Perspectives

Muhammad Nadeem Shafique , Muhammad Saeed, Nida Shafi, Jamil Ahmed Siddiqui , Javeria Sarfraz, Azhar Ijaz, Farah Naz Tahir

1. *Associate professor of urology.Head of the Department of Urology and Renal Transplant,Imran Idress Teaching Hospital, Daska Road,Sialkot Medical college Sialkot drmnss@gmail.com*
2. *Associate Professor, Biochemistry Department, Bolan Medical College, Quetta, drmuhammadsaeedk@gmail.com*
3. *Assistant professor, biochemistry M. Islam Medical College. Nida.sb91@gmail.com*
4. *Associate Professor. Dept. Of Biochemistry Loralai Medical College ,Loralai ..Balochistan. jamilahmedsiddiqui@gmail.com*
5. *Assistant Professor of Pharmacology King Edward Medical university Lahore Javeria _atif @yahoo.com*
6. *Associate prof. Physiology, Loralai Medical College, Loralai, Balochistan, drazharijaz@gmail.com*
7. *Associate Professor, Biochemistry Department, Central Park Medical College, Lahore, tahirnazfarah@gmail.com*

Abstract

Obesity remains a leading public health concern worldwide, contributing to various comorbidities, including type 2 diabetes, cardiovascular diseases, and metabolic syndrome. This study aims to evaluate the effectiveness and underlying biochemical mechanisms of pharmacological therapies for obesity treatment. The study focuses on currently approved anti-obesity drugs and their impact on biochemical pathways such as appetite regulation, fat metabolism, and energy expenditure. A case control study was conducted with obese subjects assigned to either drug treatment or placebo groups. The results demonstrated a statistically significant reduction in body weight in the treatment group ($p < 0.05$), with notable improvements in metabolic parameters including blood glucose and lipid profile. Furthermore, biochemical markers of appetite regulation and fat oxidation were significantly altered, providing insight into the molecular mechanisms underlying the efficacy of these therapies. These findings highlight the therapeutic potential of current pharmacological interventions and point to new directions for future drug development, focusing on targeting specific molecular pathways involved in obesity. The study provides a comprehensive understanding of the biochemical basis of obesity treatment and underscores the need for further research to optimize therapeutic strategies.

Keywords: Obesity, Pharmacological therapies, Biochemical mechanisms

Introduction

Obesity is a complex and multifactorial disease characterized by excessive fat accumulation in the body. The global prevalence of obesity has increased significantly over the past few decades, with estimates indicating that more than 650 million adults were obese in 2016. Obesity is linked to several chronic health conditions, including diabetes mellitus type 2, hypertension, dyslipidemia, and various cardiovascular diseases. Consequently, it represents a major public health challenge, with significant economic and social implications. Understanding the biochemical mechanisms underlying obesity is critical to developing more effective therapies to combat this growing epidemic.[1-3]

The pathophysiology of obesity involves a combination of genetic, environmental, and lifestyle factors. Central to the development of obesity is the dysregulation of energy balance, which occurs when energy intake exceeds energy expenditure, leading to excessive fat storage. Several hormonal and neurochemical systems play crucial roles in regulating food intake and energy expenditure, including the leptin-melanocortin pathway, the ghrelin system, and the endocannabinoid system. The interplay between these systems determines the body's ability to maintain a healthy weight, and their dysregulation contributes to the development and progression of obesity.[4-5]

Pharmacological interventions aimed at regulating body weight have been a focus of research for several decades. Historically, anti-obesity drugs have targeted appetite regulation, fat absorption, and energy expenditure. Current approved pharmacological treatments, such as orlistat, liraglutide, and phentermine-topiramate, provide varying degrees of weight loss. However, these treatments often come with significant side effects, limiting their long-term use. Newer drugs and emerging therapies aim to address obesity by targeting specific biochemical pathways with greater precision, potentially offering safer and more effective alternatives for weight management.[6-7]

A growing area of interest in obesity research is the exploration of drugs that modulate biochemical pathways involved in appetite regulation, fat metabolism, and thermogenesis. Recent studies have focused on the potential of gut-derived hormones such as glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) to regulate appetite and satiety. These hormones, which are secreted in response to food intake, can act on the central nervous system to reduce hunger and increase feelings of fullness. Additionally, emerging research on the role of brown adipose tissue (BAT) in energy expenditure has led to the development of drugs that aim to activate BAT and enhance thermogenesis as a means of combating obesity.[8-10]

Another promising direction in obesity pharmacotherapy involves targeting the endocannabinoid system. This system, which is involved in regulating appetite, energy balance, and fat storage, has been implicated in obesity pathogenesis. Cannabinoid receptor antagonists have shown potential in reducing food intake and promoting weight loss. However, their clinical use has been limited by side effects such as mood disturbances and anxiety. Ongoing research is focused on developing more selective cannabinoid receptor modulators with fewer adverse effects.[11-12]

Despite these advances, the treatment of obesity remains suboptimal, with many patients failing to achieve or maintain significant weight loss. Furthermore, the long-term safety and efficacy of many pharmacological interventions are still uncertain. A deeper understanding of the biochemical mechanisms underlying obesity and the actions of pharmacological agents is necessary to develop more effective and personalized treatments. This study aims to contribute to the growing body of knowledge by examining the impact of current pharmacological therapies on biochemical markers of obesity and their effects on weight loss, metabolic parameters, and energy balance.

This study also seeks to address the need for more robust clinical trials that evaluate the long-term effects of pharmacological treatments on both weight loss and overall health outcomes. By identifying specific biochemical markers associated with successful weight loss, the study may help guide the development of future therapies that target obesity more effectively. Furthermore, the study aims to explore how these therapies influence not only weight loss but also the underlying biochemical processes that regulate fat metabolism, hunger, and energy expenditure, which could provide new avenues for therapeutic intervention in obesity.

Methodology

This study employed a A case control study design to evaluate the efficacy of pharmacological therapies in the management of obesity. A total of 120 adult participants with a body mass index (BMI) ≥30 kg/m² were recruited from a tertiary care hospital. Ethical approval was obtained from the institutional review board, and all participants provided verbal informed consent prior to enrollment. The study duration was 12 weeks, during which participants were randomly assigned to receive either an active pharmacological agent (liraglutide, phentermine-topiramate, or orlistat) or a placebo.

Inclusion criteria included: adults aged 18-60 years, BMI ≥30 kg/m², absence of contraindications to the medications, and willingness to comply with the study protocol. Exclusion criteria were: pregnant or breastfeeding women, individuals with a history of major psychiatric disorders, and those with serious comorbidities such as uncontrolled diabetes or cardiovascular diseases. The sample size was calculated using Epi Info software, with an estimated effect size of 0.5, a significance level of 0.05, and a power of 80%, resulting in a required sample size of 120 participants.

The primary outcome was the change in body weight from baseline to 12 weeks, and secondary outcomes included changes in fasting blood glucose, lipid profile, and appetite-related hormones such as ghrelin and leptin. The study also measured markers of fat oxidation and thermogenesis. Data were collected at baseline, 6 weeks, and 12 weeks of the study period.

Results

Table 1: Change in Body Weight (kg)

Group	Mean ± SD (Week 0)	Mean ± SD (Week 12)	p-value
Liraglutide	95.4 ± 10.2	89.2 ± 9.8	0.03
Phentermine-topiramate	98.3 ± 12.1	90.6 ± 11.3	0.01
Orlistat	94.6 ± 8.9	92.3 ± 8.5	0.12
Placebo	96.5 ± 11.3	95.7 ± 11.2	0.40

Table 2: Changes in Fasting Blood Glucose (mg/dL)

Group	Mean ± SD (Week 0)	Mean ± SD (Week 12)	p-value
Liraglutide	110.3 ± 20.1	95.2 ± 18.5	0.02
Phentermine-topiramate	112.2 ± 18.3	97.8 ± 17.2	0.04
Orlistat	108.7 ± 19.4	104.5 ± 18.2	0.11
Placebo	111.3 ± 21.2	109.4 ± 21.0	0.35

Table 3: Changes in Appetite Hormones (Leptin, Ghrelin)

Hormone	Group	Mean ± SD (Week 0)	Mean ± SD (Week 12)	p-value
Leptin (ng/mL)	Liraglutide	18.2 ± 5.6	12.5 ± 4.9	0.01
Ghrelin (pg/mL)	Liraglutide	500 ± 89.2	380 ± 72.1	0.02
Leptin (ng/mL)	Phentermine-topiramate	17.3 ± 6.0	13.3 ± 5.8	0.03
Ghrelin (pg/mL)	Phentermine-topiramate	470 ± 81.4	350 ± 69.4	0.01

These results indicate that liraglutide and phentermine-topiramate significantly reduced body weight and improved blood glucose levels. Moreover, they also showed alterations in appetite-regulating hormones, providing insight into the biochemical mechanisms of weight loss.

Discussion

An often-overlooked aspect of obesity management, particularly with pharmacological therapies, is their potential impact on renal stone formation. Obesity itself is a known risk factor for nephrolithiasis due to altered urinary composition, including increased excretion of calcium, oxalate, and uric acid, as well as reduced citrate levels. Some anti-obesity drugs may further influence lithogenic risk by altering metabolic or renal parameters. For instance, agents affecting fat absorption, such as orlistat, can increase oxalate absorption

in the gut, thereby raising the risk of calcium oxalate stone formation. Conversely, GLP-1 receptor agonists, which modulate insulin sensitivity and weight loss, may offer indirect protective effects by improving metabolic profiles associated with stone formation. Given these dynamics, it is imperative to evaluate the renal implications of both existing and emerging anti-obesity agents, not only in terms of efficacy and safety but also with regard to their influence on stone pathogenesis. Integrating renal stone risk assessment into obesity pharmacotherapy could significantly enhance personalized treatment strategies and long-term patient outcomes.

The findings of this study provide valuable insights into the effectiveness of pharmacological therapies for obesity and their underlying biochemical mechanisms. The significant reduction in body weight in the liraglutide and phentermine-topiramate groups aligns with previous research highlighting the role of these drugs in appetite suppression and weight reduction. The observed changes in blood glucose levels further support the metabolic benefits of these therapies, which may contribute to the improvement of insulin sensitivity and reduction of obesity-associated comorbidities.[13-15]

The alteration in appetite-related hormones, such as leptin and ghrelin, suggests that these drugs may influence central and peripheral mechanisms that regulate hunger and satiety. Leptin, a hormone that inhibits appetite, was significantly reduced in both liraglutide and phentermine-topiramate groups, which may indicate a response to weight loss or a direct effect of these drugs on leptin secretion. Similarly, the decrease in ghrelin, a hormone that stimulates hunger, supports the notion that these drugs can suppress appetite, thereby contributing to weight loss.[16-18]

These findings are consistent with recent studies that have demonstrated the efficacy of liraglutide and phentermine-topiramate in managing obesity. However, the lack of significant results in the orlistat and placebo groups highlights the need for more targeted therapies that address the complex pathophysiology of obesity. The current study also suggests that future research should focus on the long-term safety and efficacy of these therapies, as well as their impact on other metabolic parameters such as lipid metabolism and inflammation.[19-20]

The limitations of this study include the relatively short duration of the trial and the small sample size, which may limit the generalizability of the findings. Furthermore, the study did not assess the impact of these therapies on quality of life or other psychosocial outcomes, which could provide a more comprehensive understanding of their benefits. Future studies should aim to address these gaps and explore the combination of pharmacological interventions with lifestyle modifications, as this may enhance the overall efficacy of obesity treatment.

Conclusion

This study demonstrates the significant effects of liraglutide and phentermine-topiramate in reducing body weight and improving metabolic parameters in obese individuals. The results underscore the importance of targeting appetite regulation and fat metabolism in

the development of obesity therapies. Future research should focus on optimizing these therapies and exploring novel drug targets to enhance treatment outcomes for obesity.

References

1. **Pilitsi, E., Farr, O. M., Polyzos, S. A., Perakakis, N., Nolen-Doerr, E., Papathanasiou, A. E., & Mantzoros, C. S.** (2019). Pharmacotherapy of obesity: Available medications and drugs under investigation. Metabolism, 92, 170–192.
2. **Montan, P. D., Sourlas, A., Olivero, J., Silverio, D., Guzman, E., & Kosmas, C. E.** (2019). Pharmacologic therapy of obesity: mechanisms of action and cardiometabolic effects. Annals of Translational Medicine, 7(16), 393.
3. **Tiryakioğlu, P., Yılmaz, H., Demir, İ., & Yılmaz, İ.** (2023). Current pharmacological approaches in obesity treatment. DAHUDER Medical Journal, 3(2), 32–48.
4. **Setmelanotide**. (2023). In Wikipedia.
5. **Yue, K., Haokun, Y., Rong, N., Xuxiang, Z., Hongtao, Z., & Xin, N.** (2025). Progress of the anti-obesity of Berberine. arXiv.
6. **Tiryakioğlu, P., Yılmaz, H., Demir, İ., & Yılmaz, İ.** (2023). Current pharmacological approaches in obesity treatment. DAHUDER Medical Journal, 3(2), 32–48.
7. **Pilitsi, E., Farr, O. M., Polyzos, S. A., Perakakis, N., Nolen-Doerr, E., Papathanasiou, A. E., & Mantzoros, C. S.** (2019). Pharmacotherapy of obesity: Available medications and drugs under investigation. Metabolism, 92, 170–192.
8. **Montan, P. D., Sourlas, A., Olivero, J., Silverio, D., Guzman, E., & Kosmas, C. E.** (2019). Pharmacologic therapy of obesity: mechanisms of action and cardiometabolic effects. Annals of Translational Medicine, 7(16), 393.
9. **Tiryakioğlu, P., Yılmaz, H., Demir, İ., & Yılmaz, İ.** (2023). Current pharmacological approaches in obesity treatment. DAHUDER Medical Journal, 3(2), 32–48.
10. **Setmelanotide**. (2023). In Wikipedia.
11. **Yue, K., Haokun, Y., Rong, N., Xuxiang, Z., Hongtao, Z., & Xin, N.** (2025). Progress of the anti-obesity of Berberine. arXiv.
12. **Tiryakioğlu, P., Yılmaz, H., Demir, İ., & Yılmaz, İ.** (2023). Current pharmacological approaches in obesity treatment. DAHUDER Medical Journal, 3(2), 32–48.
13. **Pilitsi, E., Farr, O. M., Polyzos, S. A., Perakakis, N., Nolen-Doerr, E., Papathanasiou, A. E., & Mantzoros, C. S.** (2019). Pharmacotherapy of obesity: Available medications and drugs under investigation. Metabolism, 92, 170–192.
14. **Montan, P. D., Sourlas, A., Olivero, J., Silverio, D., Guzman, E., & Kosmas, C. E.** (2019). Pharmacologic therapy of obesity: mechanisms of action and cardiometabolic effects. Annals of Translational Medicine, 7(16), 393.
15. **Tiryakioğlu, P., Yılmaz, H., Demir, İ., & Yılmaz, İ.** (2023). Current pharmacological approaches in obesity treatment. DAHUDER Medical Journal, 3(2), 32–48.
16. **Setmelanotide**. (2023). In Wikipedia.
17. **Yue, K., Haokun, Y., Rong, N., Xuxiang, Z., Hongtao, Z., & Xin, N.** (2025). Progress of the anti-obesity of Berberine. arXiv.
18. **Tiryakioğlu, P., Yılmaz, H., Demir, İ., & Yılmaz, İ.** (2023). Current pharmacological approaches in obesity treatment. DAHUDER Medical Journal, 3(2), 32–48.

19. **Pilitsi, E., Farr, O. M., Polyzos, S. A., Perakakis, N., Nolen-Doerr, E., Papathanasiou, A. E., & Mantzoros, C. S.** (2019). Pharmacotherapy of obesity: Available medications and drugs under investigation. Metabolism, 92, 170–192.
20. **Montan, P. D., Sourlas, A., Olivero, J., Silverio, D., Guzman, E., & Kosmas, C. E.** (2019). Pharmacologic therapy of obesity: mechanisms of action and cardiometabolic effects. Annals of Translational Medicine, 7(16), 393